References
1. Meena JP, Kumar Gupta A, Tanwar P, Ram Jat K, Mohan Pandey R, Seth R.
Clinical presentations and outcomes of children with cancer and
COVID-19: A systematic review. Pediatr Blood Cancer .
2021;68(6):e29005. doi:10.1002/pbc.29005
2. Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of
COVID-19 disease in pediatric oncology patients: The New York-New Jersey
regional experience. Pediatr Blood Cancer . 2021;68(3):e28843.
doi:10.1002/pbc.28843
3. Schmidt KLJ, Dautzenberg NMM, Hoogerbrugge PM, et al. Immune Response
following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer
Patients. Cancers (Basel) . 2023;15(9):2562.
doi:10.3390/cancers15092562
4. Lehrnbecher T, Sack U, Speckmann C, et al. Longitudinal Immune
Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease
2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer.Clin Infect Dis . 2023;76(3):e510-e513. doi:10.1093/cid/ciac570
5. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2
messenger RNA vaccines in patients with cancer. Cancer Cell .
2021;39(8):1091-1098.e2. doi:10.1016/j.ccell.2021.06.009
6. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates
following COVID-19 vaccination among patients with cancer. Cancer
Cell . 2021;39(8):1081-1090.e2. doi:10.1016/j.ccell.2021.06.002
7. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to
COVID-19 mRNA vaccines in hematologic malignancies patients.medRxiv . Published online April 7, 2021:2021.04.06.21254949.
doi:10.1101/2021.04.06.21254949
8. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose
SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.JAMA . 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489
9. Hall VG, Ferreira VH, Ku T, et al. Randomized Trial of a Third Dose
of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med .
2021;385(13):1244-1246. doi:10.1056/NEJMc2111462
10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels
are highly predictive of immune protection from symptomatic SARS-CoV-2
infection. Nat Med . 2021;27(7):1205-1211.
doi:10.1038/s41591-021-01377-8
11. Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines:
delivering protective immunity. BMJ . 2020;371:m4838.
doi:10.1136/bmj.m4838
12. Fauci AS. Mechanisms of corticosteroid action on lymphocyte
subpopulations. II. Differential effects of in vivo hydrocortisone,
prednisone and dexamethasone on in vitro expression of lymphocyte
function. Clin Exp Immunol . 1976;24(1):54-62.